IGAN
MCID: IGG001
MIFTS: 48

Iga Glomerulonephritis (IGAN)

Categories: Immune diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Iga Glomerulonephritis

MalaCards integrated aliases for Iga Glomerulonephritis:

Name: Iga Glomerulonephritis 12 15 17 71
Iga Nephropathy 12 74 52 15
Glomerulonephritis, Iga 52 43
Primary Immunoglobulin a Nephropathy 71
Berger's Iga or Igg Nephropathy 12
Segmental Glomerulonephritis 12
Focal Glomerulonephritis 12
Glomerulonephritis Focal 54
Primary Iga Nephropathy 12
Nephritis, Iga Type 52
Berger's Disease 52
Berger Disease 52
Igan 52

Classifications:



External Ids:

Disease Ontology 12 DOID:2986
MeSH 43 D005922
NCIt 49 C35280
SNOMED-CT 67 236407003
UMLS 71 C0017661 C3161650

Summaries for Iga Glomerulonephritis

NIH Rare Diseases : 52 IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. IgA nephropathy can occur at any age, even in childhood. After many years, deposits of IgA may cause the kidneys to leak blood and sometimes protein in the urine. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. After 10 to 20 years, the kidneys may show signs of damage and 20-40% of adults develop end-stage kidney disease. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver , celiac disease , and HIV infection . Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23). There is no cure for this condition. Treatment focuses on slowing the disease and preventing complications.

MalaCards based summary : Iga Glomerulonephritis, also known as iga nephropathy, is related to iga nephropathy 1 and glomerulonephritis. An important gene associated with Iga Glomerulonephritis is CD79A (CD79a Molecule), and among its related pathways/superpathways are Staphylococcus aureus infection and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are immune system and renal/urinary system

Disease Ontology : 12 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus.

Wikipedia : 74 IgA nephropathy (IgAN), also known as Berger's disease (/bɛərˈʒeɪ/) (and variations), or synpharyngitic... more...

Related Diseases for Iga Glomerulonephritis

Diseases related to Iga Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 701)
# Related Disease Score Top Affiliating Genes
1 iga nephropathy 1 32.8 NPHS1 MASP1 FCAR CD79A C1GALT1 AGTR1
2 glomerulonephritis 31.5 NPHS1 MBL2 MASP1 CD79A CD40LG ALB
3 purpura 31.3 CD79A CD40LG ACE
4 immune-complex glomerulonephritis 31.3 CFHR2 CD40LG ALB
5 acute kidney tubular necrosis 31.2 REN CD40LG ALB ACE
6 polycystic kidney disease 31.1 REN ALB AGTR1 ACE
7 celiac disease 1 31.1 CD79A CD40LG CCR6 ALB
8 mesangial proliferative glomerulonephritis 31.1 MBL2 CFHR2 CD79A CD40LG
9 renal hypertension 31.0 REN NPHS1 ALB AGTR1 ACE
10 chlamydia 31.0 MBL2 CD79A CD40LG
11 diffuse glomerulonephritis 31.0 MASP1 CD40LG
12 pyelonephritis 31.0 MBL2 ALB ACE
13 vasculitis 31.0 PTX3 MBL2 CD79A CD40LG
14 eclampsia 30.9 REN ALB ACE
15 end stage renal disease 30.9 REN NPHS1 ALB AGTR1 ACE
16 immune deficiency disease 30.9 MBL2 CFHR2 CD79A CD40LG CCR6
17 autosomal dominant polycystic kidney disease 30.9 REN ALB AGTR1 ACE
18 pre-eclampsia 30.9 REN CD40LG ALB AGTR1 ACE
19 exudative glomerulonephritis 30.9 CFHR2 CD40LG
20 membranoproliferative glomerulonephritis 30.8 NPHS1 CFHR2 CD79A ALB
21 hemolytic uremic syndrome, atypical 1 30.8 PTX3 MBL2 MASP1 CFHR2
22 acute cystitis 30.8 REN CD40LG CCR6 ALB ACE
23 spondyloarthropathy 1 30.8 FCAR CFHR2 CD40LG CCR6
24 c1q nephropathy 30.8 CD79A CD40LG
25 typhoid fever 30.8 CD40LG CCR6 ALB
26 otitis media 30.8 MBL2 CD79A CD40LG ALB
27 bacteriuria 30.8 CD79A CD40LG ALB
28 kidney disease 30.8 REN NPHS1 CD79A ALB AGTR1 ACE
29 hypertensive nephropathy 30.8 ALB AGTR1 ACE
30 acquired immunodeficiency syndrome 30.8 CD79A CD40LG CCR6 ALB
31 chickenpox 30.7 CD40LG CCR6 ALB
32 portal hypertension 30.7 CD40LG ALB AGTR1 ACE
33 malignant hypertension 30.7 REN CFHR2 AGTR1 ACE
34 idiopathic nephrotic syndrome 30.7 ALB ACE
35 immunoglobulin g deficiency 30.7 MBL2 CD79A CD40LG
36 nephrosclerosis 30.7 NPHS1 AGTR1 ACE
37 exanthem 30.7 CD40LG CCR6 ALB ACE
38 pustulosis palmaris et plantaris 30.7 CD79A CD40LG CCR6
39 arteriolosclerosis 30.6 REN CD79A ALB
40 complement component 3 deficiency 30.6 MBL2 MASP1 CFHR2
41 pulmonary edema 30.6 REN AGTR1 ACE
42 sleep apnea 30.6 REN ALB ACE
43 pleural empyema 30.6 CD79A CD40LG ALB
44 collagen disease 30.6 MBL2 CD40LG CCR6
45 thrombocytopenia due to platelet alloimmunization 30.6 PF4 CD40LG CCR6
46 chronic graft versus host disease 30.6 CD79A ALB
47 vascular disease 30.6 REN PF4 CD40LG ALB AGTR1 ACE
48 focal segmental glomerulosclerosis 30.6 NPHS1 ALB AGTR1 ACE
49 glomerular disease 30.6 NPHS1 MIR30A CD79A ALB ACE
50 monoclonal gammopathy of uncertain significance 30.5 CFHR2 CD40LG CCR6

Graphical network of the top 20 diseases related to Iga Glomerulonephritis:



Diseases related to Iga Glomerulonephritis

Symptoms & Phenotypes for Iga Glomerulonephritis

MGI Mouse Phenotypes related to Iga Glomerulonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 ACE AGTR1 ALB C1GALT1 CCR6 CD40LG
2 renal/urinary system MP:0005367 9.28 ACE AGTR1 ALB C1GALT1 CD40LG CD79A

Drugs & Therapeutics for Iga Glomerulonephritis

Drugs for Iga Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Probucol Approved, Investigational Phase 4 23288-49-5 4912
6
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
rituximab Approved Phase 4 174722-31-7 10201696
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
11
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
12
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
15
Azathioprine Approved Phase 4 446-86-6 2265
16
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
19
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
20
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
21 Interferon-alpha Phase 4
22 interferons Phase 4
23 Mitogens Phase 4
24 Cassava Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Antimalarials Phase 4
28 Anti-Infective Agents Phase 4
29 Antitubercular Agents Phase 4
30 Anti-Bacterial Agents Phase 4
31 Tripterygium Phase 4
32 Protective Agents Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Angiotensin-Converting Enzyme Inhibitors Phase 4
35 HIV Protease Inhibitors Phase 4
36
protease inhibitors Phase 4
37 Antioxidants Phase 4
38 Lipid Regulating Agents Phase 4
39 Hypolipidemic Agents Phase 4
40 Anticholesteremic Agents Phase 4
41 Antimetabolites Phase 4
42 Antiemetics Phase 4
43 Neuroprotective Agents Phase 4
44 Gastrointestinal Agents Phase 4
45 Micronutrients Phase 4
46 Vitamins Phase 4
47 Trace Elements Phase 4
48 Vasoconstrictor Agents Phase 4
49 Nutrients Phase 4
50 Calcium, Dietary Phase 4

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
2 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
3 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
4 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
5 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
6 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
7 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
8 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
9 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
10 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
11 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
12 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
13 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
14 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
15 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
16 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
17 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
18 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
19 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
20 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
21 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
22 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
23 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
24 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
25 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
26 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
27 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
28 A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
29 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
30 An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Completed NCT02282930 Phase 3 ACTH (Acthar) Gel
31 A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Completed NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
32 A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy Completed NCT02232776 Phase 3 Losartan
33 Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
34 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
35 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
36 Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
37 Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial Completed NCT00437463 Phase 3 Ramipril
38 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
39 A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
40 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
41 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) Recruiting NCT03608033 Phase 3
42 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie Herbal Compound;Immunosuppressive Agents
43 A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy Recruiting NCT03762850 Phase 3 sparsentan;irbesartan
44 Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
45 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
46 A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
47 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
48 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Withdrawn NCT00599963 Phase 3 paricalcitol
49 Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
50 A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy Completed NCT02112838 Phase 2 Fostamatinib 150 mg;Fostamatinib 100 mg;Placebo

Search NIH Clinical Center for Iga Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, iga

Genetic Tests for Iga Glomerulonephritis

Anatomical Context for Iga Glomerulonephritis

MalaCards organs/tissues related to Iga Glomerulonephritis:

40
Kidney, Liver, T Cells, Tonsil, Monocytes, B Cells, Skin

Publications for Iga Glomerulonephritis

Articles related to Iga Glomerulonephritis:

(show top 50) (show all 6778)
# Title Authors PMID Year
1
Glomerular deposition of mannose-binding lectin in human glomerulonephritis. 61 54
10328463 1999
2
Hypercholesterolemia and glomerular diseases in urinary screening of school children. 61 54
10228998 1999
3
Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. 61 54
9176853 1997
4
Serum carnitine concentrations in different glomerular diseases with normal renal function. 61 54
8699613 1996
5
Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy. 61
32524871 2020
6
Circulating inflammation-related factors are correlated with systemic redox status in IgA nephropathy; a case-control study. 61
32428564 2020
7
Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study. 61
32197881 2020
8
Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. 61
32418621 2020
9
Tonsillar immunology in IgA nephropathy. 61
32534712 2020
10
T lymphocytes in IgA nephropathy. 61
32509008 2020
11
Genetic variants of the MIR31HG gene are related to a risk of IgA nephropathy. 61
32344354 2020
12
IgA Nephropathy Benefits from Compound K Treatment by Inhibiting NF-κB/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. 61
32482710 2020
13
Expression of miRNA-223 and NLRP3 gene in IgA patients and intervention of traditional Chinese medicine. 61
32489289 2020
14
Triptolide inhibits tonsillar IgA production by upregulating FDC-SP in IgA nephropathy. 61
31815288 2020
15
MicroRNA-21-5p participates in IgA nephropathy by driving T helper cell polarization. 61
31863364 2020
16
Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. 61
32518868 2020
17
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. 61
30418652 2020
18
Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria. 61
32541473 2020
19
Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience. 61
32507961 2020
20
IgA Staining Patterns Differentiate Between IgA Nephropathy and IgA-Dominant Infection-Associated Glomerulonephritis. 61
32518872 2020
21
Crescentic IgA nephropathy in children. 61
31993782 2020
22
Renal survival and risk factors in IgA nephropathy with crescents. 61
32533530 2020
23
Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis. 61
32519999 2020
24
Cancer development and mortality differences in patients with glomerulonephritis after renal biopsy: a single center retrospective cohort study. 61
32522167 2020
25
A case of glomerulonephritis caused by brucellosis. 61
32508259 2020
26
Spondyloarthritis-Associated IgA Nephropathy. 61
32518863 2020
27
Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy. 61
31838587 2020
28
Identification of children with chronic kidney disease through school urinary screening using urinary protein/creatinine ratio measurement: an observational study. 61
32006130 2020
29
Activation of Complement System in Henoch-Schönlein Purpura Nephritis. 61
32400248 2020
30
Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch-Schönlein purpura nephritis. 61
32408340 2020
31
Comparison of clinicopathological features and prognosis between IgA nephropathy and purpura nephritis in adults with diffuse endocapillary proliferation: a single-center cohort study. 61
32389007 2020
32
Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low-dose prednisone. 61
32266035 2020
33
Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: a single-center observational study in Italy. 61
31977575 2020
34
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. 61
32464215 2020
35
Clinical and histological differences between adults and children in new onset IgA nephropathy. 61
32444925 2020
36
Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy. 61
32523959 2020
37
Comparative proteomic analysis of renal proteins from IgA nephropathy model mice and control mice. 61
32436031 2020
38
Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial. 61
32535481 2020
39
The TLR4-MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy. 61
32388684 2020
40
Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement. 61
32048072 2020
41
Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report. 61
32481351 2020
42
The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. 61
32278618 2020
43
A Rare Clinical Presentation of Metastatic Crohn's Disease. 61
32467818 2020
44
Inguinal Herniation After Living Donor Kidney Transplantation: A Case Report. 61
32448665 2020
45
Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. 61
32447619 2020
46
Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schönlein purpura. 61
31932958 2020
47
Arteriolar C4d in IgA Nephropathy: A Cohort Study. 61
32439421 2020
48
MicroRNA‑196b targets COSMC in pediatric IgA nephropathy. 61
32186752 2020
49
IgA nephropathy: A brief review. 61
32241578 2020
50
Hematopoietic stem cell donor with IgA nephropathy: Challenges and management algorithm. 61
32409153 2020

Variations for Iga Glomerulonephritis

Expression for Iga Glomerulonephritis

Search GEO for disease gene expression data for Iga Glomerulonephritis.

Pathways for Iga Glomerulonephritis

Pathways related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.31 MBL2 MASP1 FCAR
2
Show member pathways
11.03 REN AGTR1 ACE
3 10.64 REN AGTR1 ACE

GO Terms for Iga Glomerulonephritis

Cellular components related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 REN PTX3 PLA2R1 PF4 MBL2 MASP1
2 extracellular space GO:0005615 9.32 REN PTX3 PF4 MIR30A MIR148B MBL2

Biological processes related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta metabolic process GO:0050435 9.46 REN ACE
2 angiotensin maturation GO:0002003 9.43 REN ACE
3 killing by host of symbiont cells GO:0051873 9.4 PF4 MBL2
4 complement activation, lectin pathway GO:0001867 9.37 MBL2 MASP1
5 opsonization GO:0008228 9.32 PTX3 MBL2
6 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.26 AGTR1 ACE
7 renin-angiotensin regulation of aldosterone production GO:0002018 9.16 REN AGTR1
8 O-glycan processing, core 1 GO:0016267 8.96 C1GALT1C1 C1GALT1
9 kidney development GO:0001822 8.92 REN C1GALT1 AGTR1 ACE

Molecular functions related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity GO:0016263 8.96 C1GALT1C1 C1GALT1
2 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Iga Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....